FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3179522133> ?p ?o ?g. }

• W3179522133 endingPage "7212" @default.
• W3179522133 startingPage "7212" @default.
• W3179522133 abstract "Mild to moderate COVID-19 can be found in about 80% of patients. Although mortality is low, mild to moderate COVID-19 may progress to severe or even critical stages in about one week. This poses a substantial burden on the health care system, and ultimately culminates in death or incapacitation and hospitalization. Therefore, pharmacological treatment is paramount for patients with this condition, especially those with recognized risk factors to disease progression. We conducted a comprehensive review in the medical literature searching for randomized studies carried out in patients with mild to moderate COVID-19. A total of 14 randomized studies were identified, enrolling a total of 6848 patients. Nine studies (64%) were randomized, placebo-controlled trials, whereas five were open-label randomized trials (35%). We observed that Bamlanivimab and nitazoxanide reduced viral load, whereas ivermectin may have shortened time to viral clearance; Interferon Beta-1 reduced time to viral clearance and vitamin D reduced viral load; Favirapir, peginterferon, and levamisole improved clinical symptoms, whereas fluvoxamine halted disease progression; inhaled budesonide reduced the number of hospitalizations and visits to emergency departments; colchicine reduced the number of deaths and hospitalizations. Collectively, therefore, these findings show that treatment of early COVID-19 may be associated with reduced viral load, thus potentially decreasing disease spread in the community. Moreover, treatment of patients with mild to moderate COVID-19 may also be associated with improved clinical symptoms, hospitalization, and disease progression. We suggest that colchicine, inhaled budesonide, and nitazoxanide, along with nonpharmacological measures, based on efficacy and costs, may be used to mitigate the effects of the COVID-19 pandemic in middle-income countries." @default.
• W3179522133 created "2021-07-19" @default.
• W3179522133 creator A5049520380 @default.
• W3179522133 creator A5054700572 @default.
• W3179522133 creator A5072650956 @default.
• W3179522133 date "2021-07-05" @default.
• W3179522133 modified "2023-09-24" @default.
• W3179522133 title "Pharmacological Treatment of Patients with Mild to Moderate COVID-19: A Comprehensive Review" @default.
• W3179522133 cites W2017248106 @default.
• W3179522133 cites W2150120685 @default.
• W3179522133 cites W2153720904 @default.
• W3179522133 cites W2517547699 @default.
• W3179522133 cites W2588906490 @default.
• W3179522133 cites W2601577524 @default.
• W3179522133 cites W2618198971 @default.
• W3179522133 cites W2914443670 @default.
• W3179522133 cites W3008028633 @default.
• W3179522133 cites W3011610993 @default.
• W3179522133 cites W3012849736 @default.
• W3179522133 cites W3016746341 @default.
• W3179522133 cites W3023489051 @default.
• W3179522133 cites W3023606094 @default.
• W3179522133 cites W3028583791 @default.
• W3179522133 cites W3037701834 @default.
• W3179522133 cites W3039624693 @default.
• W3179522133 cites W3047144258 @default.
• W3179522133 cites W3047719754 @default.
• W3179522133 cites W3080718665 @default.
• W3179522133 cites W3081073771 @default.
• W3179522133 cites W3081594520 @default.
• W3179522133 cites W3085370564 @default.
• W3179522133 cites W3086924588 @default.
• W3179522133 cites W3087151262 @default.
• W3179522133 cites W3092775354 @default.
• W3179522133 cites W3094324484 @default.
• W3179522133 cites W3098266159 @default.
• W3179522133 cites W3099947806 @default.
• W3179522133 cites W3102920585 @default.
• W3179522133 cites W3107056972 @default.
• W3179522133 cites W3111431752 @default.
• W3179522133 cites W3117275749 @default.
• W3179522133 cites W3125712166 @default.
• W3179522133 cites W3127381644 @default.
• W3179522133 cites W3127453447 @default.
• W3179522133 cites W3129183114 @default.
• W3179522133 cites W3135420706 @default.
• W3179522133 cites W3137936874 @default.
• W3179522133 cites W3155314613 @default.
• W3179522133 cites W3164932383 @default.
• W3179522133 cites W3165656738 @default.
• W3179522133 doi "https://doi.org/10.3390/ijerph18137212" @default.
• W3179522133 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8297311" @default.
• W3179522133 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34281149" @default.
• W3179522133 hasPublicationYear "2021" @default.
• W3179522133 type Work @default.
• W3179522133 sameAs 3179522133 @default.
• W3179522133 citedByCount "9" @default.
• W3179522133 countsByYear W31795221332021 @default.
• W3179522133 countsByYear W31795221332022 @default.
• W3179522133 countsByYear W31795221332023 @default.
• W3179522133 crossrefType "journal-article" @default.
• W3179522133 hasAuthorship W3179522133A5049520380 @default.
• W3179522133 hasAuthorship W3179522133A5054700572 @default.
• W3179522133 hasAuthorship W3179522133A5072650956 @default.
• W3179522133 hasBestOaLocation W31795221331 @default.
• W3179522133 hasConcept C126322002 @default.
• W3179522133 hasConcept C142462285 @default.
• W3179522133 hasConcept C142724271 @default.
• W3179522133 hasConcept C168563851 @default.
• W3179522133 hasConcept C203014093 @default.
• W3179522133 hasConcept C204787440 @default.
• W3179522133 hasConcept C27081682 @default.
• W3179522133 hasConcept C2777182164 @default.
• W3179522133 hasConcept C2777276848 @default.
• W3179522133 hasConcept C2779123688 @default.
• W3179522133 hasConcept C2779134260 @default.
• W3179522133 hasConcept C3008058167 @default.
• W3179522133 hasConcept C3013748606 @default.
• W3179522133 hasConcept C524204448 @default.
• W3179522133 hasConcept C71924100 @default.
• W3179522133 hasConceptScore W3179522133C126322002 @default.
• W3179522133 hasConceptScore W3179522133C142462285 @default.
• W3179522133 hasConceptScore W3179522133C142724271 @default.
• W3179522133 hasConceptScore W3179522133C168563851 @default.
• W3179522133 hasConceptScore W3179522133C203014093 @default.
• W3179522133 hasConceptScore W3179522133C204787440 @default.
• W3179522133 hasConceptScore W3179522133C27081682 @default.
• W3179522133 hasConceptScore W3179522133C2777182164 @default.
• W3179522133 hasConceptScore W3179522133C2777276848 @default.
• W3179522133 hasConceptScore W3179522133C2779123688 @default.
• W3179522133 hasConceptScore W3179522133C2779134260 @default.
• W3179522133 hasConceptScore W3179522133C3008058167 @default.
• W3179522133 hasConceptScore W3179522133C3013748606 @default.
• W3179522133 hasConceptScore W3179522133C524204448 @default.
• W3179522133 hasConceptScore W3179522133C71924100 @default.
• W3179522133 hasIssue "13" @default.
• W3179522133 hasLocation W31795221331 @default.
• W3179522133 hasLocation W31795221332 @default.

• next